$10M at Risk: D.C. Circuit Could Overturn Cannabis Schedule III, Shaking Market

For cannabis investors and market participants, the Schedule III transition has been the linchpin of a turn‑around story. If the D.C. Circuit finds the AG’s order procedurally invalid, companies counting on 280E tax relief and institutional capital could see those advantages disappear overnight, triggering a sector‑wide repricing.

The D.C. Circuit Court of Appeals is set to decide a pivotal case that could upend the Biden-era rescheduling of marijuana and redefine the limits of executive authority under the Controlled Substances Act (CSA). In April 2026, the U.S. Attorney General issued an order moving state-licensed medical marijuana from Schedule I to Schedule III while simultaneously establishing a novel federal registration framework for state cannabis businesses. MMJ International Holdings, a pharmaceutical company developing FDA-regulated cannabinoid drugs, has petitioned the court to invalidate the order, arguing that the Attorney General bypassed the formal rulemaking procedures that Congress mandated for such a fundamental change in drug policy.

“

Circuit Court of Appeals is set to decide a pivotal case that could upend the Biden-era rescheduling of marijuana and redefine the limits of executive authority under the Controlled Substances Act (CSA).

At the heart of the dispute is Section 201 of the CSA (21 U.S.C. § 811), which normally requires the Drug Enforcement Administration to conduct "rule making on the record after opportunity for a hearing" when altering a substance's schedule. MMJ contends that the Attorney General improperly relied upon a treaty‑based provision (likely § 811(d)) as a shortcut, avoiding the public hearings, cross‑examination of witnesses, and formal record that would be required in a typical rescheduling proceeding. This procedural choice, the company asserts, not only deprived interested parties of due process but also produced an order that fails to address how state‑licensed marijuana businesses can coexist with the FDA’s rigorous drug approval pathway—a direct threat to MMJ’s decade‑long, $10‑million investment in cannabinoid medicines for Huntington’s disease and multiple sclerosis.

The implications stretch far beyond cannabis. A ruling in MMJ’s favor would confirm that the CSA’s procedural safeguards serve as a meaningful check on executive action, forcing any future rescheduling—whether of psychedelics, stimulants, or other controlled substances—to withstand the scrutiny of formal administrative proceedings. Conversely, if the court upholds the order, it would signal that the Attorney General retains broad discretion to realign drug schedules through expedited means, potentially opening the door to rapid policy swings with each new administration. Administrative law scholars are watching closely because the D.C. Circuit’s interpretation of "on the record" rulemaking could reverberate across other regulatory domains where Congress has prescribed similar hearing requirements.